biotech · PTSD - Post Traumatic Stress Disorder · P1b: Advanced Solid Tumors · CMPX
Compass Therapeutics
Compass Therapeutics is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker CMPX. Primary therapeutic focus areas include PTSD - Post Traumatic Stress Disorder, P1b: Advanced Solid Tumors,
80 Guest Street, Suite 601, Boston, MA 02135, US HQ
2014 Founded
54 Employees
Public company Type
CMPX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 80 Guest Street, Suite 601, Boston, MA 02135, US
- Founded
- 2014
- Employees
- 54
- Programs
- 15
- Drugs
- 3
- Patents
- 100
Psilocybin
Phase 2 · small molecule · Treatment-Resistant Major Depressive Disorder
Psilocybin for Treatment-Resistant Major Depressive Disorder is a Phase 2 program (small_molecule) at Compass Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code 2021P000863
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Compass Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Treatment-Resistant Major Depressive Disorder
- Status
- terminated
- Trials
- 1